We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App





Sentinel Diagnostics Develops Ready-To-Use Real-Time PCR Mix for Detection of Novel Coronavirus

By HospiMedica International staff writers
Posted on 18 Mar 2020
Sentinel Diagnostics (Milan, Italy) has announced that it has developed a ready-to-use Real-Time PCR mix for the detection of novel Coronavirus disease (COVID-19). More...
Sentinel has developed two kits in collaboration with the most important hospital lab for the detection and treatment of coronavirus in Italy.

Sentinel is focused on the development and production of in vitro diagnostics (IVD) for the most advanced clinical chemistry, immunochemistry and molecular diagnostics platforms. Besides its wide product portfolio in clinical chemistry, the FOB Gold® line is Sentinel’s complete solution for colorectal cancer screening, which includes patented sampling devices and analytical systems. In the last 12 years, the company has grown in the molecular diagnostics sector and has developed the proprietary technology STAT-NAT®, able to stabilize the activity of PCR mix, allowing room temperature transport and storage, performance improvement and long shelf life. STAT-NAT® can be customized for all NAT systems, from POC to central laboratory.

Sentinel’s STAT-NAT® COVID-19 assay is a freeze-dried ready-to-use Real-Time PCR mix for the detection of novel Coronavirus disease in human respiratory tract specimens in about 90 minutes. The company has developed two versions of this kit, which follow two international protocols for the highest sensitivity and specificity. STAT-NAT® COVID-19 HK kit is based on the Hong Kong protocol, while STAT-NAT® COVID-19 B assay follows the Berlin protocol. Both these kits are validated on the most common PCR instruments and have been tested on human respiratory tract specimens found positive.

“The R&D NAT team has developed and tested the COVID-19 assay by working side by side with one of the reference hospital labs for the detection and treatment of coronavirus in Italy” said Maurizio Gramegna, Chief Technology Officer at Sentinel Diagnostics. “Both STAT-NAT® COVID-19 HK and B are compliant with the international protocols and are able to detect the relevant genetic variants of Coronavirus COVID-19. We are always in touch with KOLs, in order to keep the assays up to date and even update them in case of any virus mutation.”

Related Links:
Sentinel Diagnostics


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Silver Member
X-Ray QA Device
Accu-Gold+ Touch Pro
Hemostatic Agent
HEMOBLAST Bellows
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.